AT205669B - - Google Patents
Info
- Publication number
- AT205669B AT205669B AT651258A AT651258A AT205669B AT 205669 B AT205669 B AT 205669B AT 651258 A AT651258 A AT 651258A AT 651258 A AT651258 A AT 651258A AT 205669 B AT205669 B AT 205669B
- Authority
- AT
- Austria
- Prior art keywords
- oxyalkylated
- sep
- compounds
- theophylline
- theobromine
- Prior art date
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 13
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229960000278 theophylline Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 150000003212 purines Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001813 broncholytic effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE205669T | 1956-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT205669B true AT205669B (en:Method) | 1959-10-10 |
Family
ID=29556986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT651258A AT205669B (en:Method) | 1956-05-16 | 1957-05-09 |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT205669B (en:Method) |
-
1957
- 1957-05-09 AT AT651258A patent/AT205669B/de active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2324386B1 (de) | Wässriger Cholesterin-Standard | |
| AT205669B (en:Method) | ||
| DE753235C (de) | Verfahren zur Herstellung waessriger Lactoflavinloesungen | |
| AT205670B (en:Method) | ||
| AT206587B (de) | Verfahren zur Herstellung von pharmazeutischen Präparaten, die oxyalkylierte Theophyllin- und bzw. oder oxyalkylierte Theobromverbindungen enthalten | |
| DE2021969A1 (de) | Verfahren zur Herstellung eiweissfreier Praeparate | |
| DE665707C (de) | Verfahren zur Herstellung haltbarer Zubereitungen aus Chlorophyll oder chlorophyllhaltigen Stoffen und Mononatriumphosphat | |
| EP0108248B2 (de) | Lösungsvermittlerfreie, wässrige Nitroglycerinlösung | |
| DE942534C (de) | Verfahren zur Herstellung von haltbaren und gut wirksamen Loesungen oder Suspensionen antibiotischer Mittel | |
| DE968534C (de) | Verfahren zur Herstellung von wasserloeslichen Pulvern, Tabletten und waessrigen Loesungen schwerloeslicher Salze des 1-(3, 4-Dimethoxybenzyl)-6, 7-dimethoxyisochinolinsoder 1-Benzyl-3-aethyl-6, 7-dimethoxyisochinolins | |
| DE2635293A1 (de) | Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze | |
| DE830955C (de) | Verfahren zur Herstellung bestaendiger Trinitroalkanolaminsalze | |
| DE925541C (de) | Verfahren zur Herstellung waessriger Loesungen von in Wasser schwer loeslichen Arzneimitteln | |
| DE855894C (de) | Verfahren zur Herstellung haltbarer, waessriger Loesungen von Gluconaten | |
| DE950674C (de) | Verfahren zur Gewinnung von Wirkstoffen aus waessrigen Extrakten von Echinaceen-Arten | |
| DE967872C (de) | Verfahren zur Herstellung waessriger Loesungen von in Wasser schwer loeslichen Arzneimitteln | |
| AT149825B (de) | Verfahren zur Herstellung von Alkali- bzw. Erdalkalidoppelverbindungen der Dimethylxanthine mit organischen Säuren. | |
| AT205668B (en:Method) | ||
| DE726888C (de) | Verfahren zur Herstellung von Loesungen oder Suspensionen des blutzuckersenkenden Hormons der Pankreasdruese | |
| AT99940B (de) | Verfahren zur Überführung wasserunlöslicher bzw. schwerlöslicher Arzneimittel in tropfbare und injizierbare Form. | |
| DE588046C (de) | Verfahren zur Abscheidung des Oestrushormons aus Harn | |
| DE711635C (de) | Verfahren zur Stabilisierung von Loesungen des Kreislaufhormons Kallikrein aus Pankreas | |
| DE657129C (de) | Verfahren zur Herstellung von Loesungen oder Extrakten aus Bakterien, Pollen oder sonstigen pflanzlichen Zellen | |
| DE1151096B (de) | Verfahren zur Herstellung haltbarer, konzentrierter waessriger Loesungen von oxyalkylierten Theophyllin- oder oxy-alkylierten Theobrominverbindungen | |
| DE504183C (de) | Verfahren zur Darstellung therapeutisch wertvoller, steriler und haltbarer, zu Injektionen geeigneter Loesungen von p-dialkylaminoarylphosphinigsauren Salzen |